A Phase 2 interventional study of Dose 1 of QLS1410 and Dose 2 of QLS1410 in Uncontrolled Hypertension, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to evaluate the efficacy and safety of multiple dose strengths of QLS1410 in patients with uncontrolled hypertension.
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of QLS1410 tablets in patients with uncontrolled hypertension. Approximately 260 patients will be randomized in a 1:1:1:1 ratio into 1 of the 4 treatment groups. The study will consist of the following 4 periods: A Screening Period of up to 2 weeks, A Run -in Period of 2 weeks, A Double-Blind Treatment Period of 12 weeks and A Follow-Up Period of 1 weeks.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 260 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 198 studies on the registry; 120 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dose 1 of QLS1410
Drug: Dose 2 of QLS1410
Drug: Dose 3 of QLS1410
Drug: Placebo
Patients will take oral tablets of QLS1410 once daily (QD) for 12 weeks
Patients will take oral tablets of QLS1410 once daily (QD) for 12 weeks.
Patients will take oral tablets of QLS1410 once daily (QD) for 12 weeks.
Matching placebo tablet administered orally, once daily (QD).
Primary efficacy endpoint
Change From Baseline in Mean Seated Systolic BP (SBP)
Time frame: At week 12
Safety endpoint
Number of Participants With Any Adverse Events
Time frame: 12 weeks
Efficacy endpoint
Change From Baseline in Mean Seated Systolic BP (SBP)
Time frame: At week 4 and 8
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Pharmaceutical Co., Ltd. →